Pentoxifylline for diabetic retinopathy

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Lopes De Jesus, Carlos César ^a   Atallah, A N ^b   Valente, O ^b   Moca Trevisani V F ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PENTOXIFYLLINE; PLACEBO;

ANOREXIA; BLINDNESS; BLOOD PRESSURE REGULATION; BLOOD VISCOSITY; CLINICAL TRIAL; COMORBIDITY; DATA BASE; DATA SYNTHESIS; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; GLYCEMIC CONTROL; HEADACHE; HUMAN; INFORMATION PROCESSING; KAPPA STATISTICS; LASER COAGULATION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PUBLICATION; QUALITY OF LIFE; RETINA BLOOD VESSEL OCCLUSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION; VOMITING;

EID: 44949105477     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006693.pub2     Document Type: Review

References (37)

1. Bloomgarden 1999 Bloomgarden ZT. The European Association for the Study of Diabetes Annual Meeting, 1998: The U.K. Prospective Diabetes Study and other topics in type 2 diabetes. Diabetes Care. 1999; Vol. 22:989-95.
2. Desai 2007 Desai K, Wu L. Methylglyoxal and advanced glycation endproducts: new therapeutic horizons?. Recent Patents on Cardiovascular Drug Discovery 2007;2:89-99.
3. Gincherman 1982 Gincherman EZ, Titova SI, Mazovetski AG, Perelygina AA, Gordeeva NP, Gincherman EZ, et al.Use of preparations with anti-aggregation and hemostatic action in treating diabetic retinopathy. Problemy Endokrinologii (Moskva) 1982;28:17-22.
4. Gol'tseva 1983 Gol'tseva SV, Gol'tseva SV. Comparative evaluation of the efficacy of various methods in the treatment of diabetic retinopathies. Oftalmologicheskil zhurnal 1983;38:36-8.
5. Ivanisevic 1994 Ivanisevic M. Present approach to medical therapy of diabetic retinopathy. Acta Clinica Croatica 1994;33:221-7.
6. Iwafune 1980 Iwafune Y. Clinical use of pentoxyfilline in hemorragic disorders of the retina. Pharmatherapeutica 1980;2:429-38.
7. Katznelson 1980 Katznelson LA, Mikhailova NA, Gurtovaya EE, Yakovlev AA. Results of experimental and clinical trials of the drug trental. Vestnik Oftalmologii 1980;1:41-4.
8. McCarty 1998 McCarty MF, McCarty MF. Nitric oxide deficiency, leucocyte activation, and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy / neuropathy - preventive potential of antioxidants, essential fatty acids, chromium, gingkilides, and pentoxyfilline. Medical Hypothesis 1998;50:435-49.
9. Parikh 2004 Parikh A, Fantus IG. Screening and management of diabetic microvascular complications in older adults. Geriatrics and Aging 2004;7:22-30.
10. Polunin 1993 PoluninGS, Simonova KK, Pirogova EP. Results of diabetic retinopathy treatment with angioprotectors. Vetnik oftalmologii 1993;109:27-30.
11. Radfar 2005 *Radfar M. Effects of pentoxyfilline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients: a randomized, double-blind placebo-controlled clinical trial. Biomedicine & Phar-macohterapy - Biomédecine & Pharmacothérapie 2005;59:302-6.
12. Saldan 1984 Saldan IR. Use of disaggregants in treating diabetic retinopathy. Oftalmologicheskil zhurnal 1984;7:395-8.
13. Schubotz 1975 Schubotz R. Demonstration of the effect of pentoxyfilline in arterial circulating disorders (double-blind study using Trental 400). Die Medizinische Welt 1975;26:1884-5.
14. Schubotz 1975a Schubotz R. Double-blind study with Pentoxyfilline on 50 patients with maturity-onset diabetes. Fortschritte der Medizin 1975;93:1430-2.
15. Solerte 1985 Solerte SB, Ferrari E, Solerte SB, Ferrari E. Diabetic retinal vascular complications and erythrocyte fistrability: results of a 2-year follow-up study with pentoxyfilline. Pharmatherapeutica 1985;4:341-50.
16. Sonkin 1993 Sonkin PL, Kelly LW, Sinclair SH, Hatchell DL, Sonkin PL, Kelly LW, et al.Pentoxyfilline increases retinal capillary blood flow velocity in patients with diabetes. Archives of Ophthalmology 1993;111:1647-52.
17. Wroe 2001 Wroe C. Highlights of the Diabetes UK Annual Professional Meeting: 4-6 April 2001. Practical Diabetes International. 2001; Vol. 18:217-24.
18. ADA 1997 American Diabetes Association. Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20 Suppl 1:S5-20.
19. ADA 1999 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22 Suppl 1:S5-19.
20. Balasubramanyam 2002 Balasubramanyam M, Rema M, Premanand C. Biochemical and molecular mechanisms of diabetic retinopathy. Current Science 2002;83:1506-14.
21. Borrillo 1999 Borrillo JL, Mittra RA, Dev S, Mieler WF, Pescinski S, Prasad A. Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. Transactions of the American Ophthalmological Society 1999;XCVII:435-49.
22. Cohen 1960 Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
23. Ferrari 1987 Ferrari E, Fioravanti M, Patti AL, Viola C, Solerte SB. Effects of long term (4 yeras) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients. Pharmatherapeutica 1987;5(1):26-39.
24. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 2002;21:1539-58.
25. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
26. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library 2005; Vol. 3.
27. Iwafune 1980 Iwafune Y, Yoshimoto H. Clinical use of pentoxifylline in haemorrhagic disorders of the retina. Pharmatherapeutica 1980;2(7):429-38.
28. Klein 1984 Klein R, Klein BE, Mors SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Archives of Ophthalmology 1984;102(4):532-52.
29. Lau 2006 Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597-600.
30. Moher 1999 Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports ofmeta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354(9193):1896-900.
31. Rall 1991 Goodman, Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. In: Gilman AG, Rall TW, Nies AS, Taylor P editor(s). Goodman and Gilman's The Pharmacological Basis of Therapeutics. Eighth edition. Rio de Janeiro: Editora Guanabara Koogan S.A, 1991:408-14.
32. Solerte 1985 Solerte SB, Ferrari E. Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline. Pharmatherapeutica 1985;4(6):341-50.
33. Sonkin 1992 Sonkin PL, Kelly LW, Sinclair SH, Hatchell DL. Pentoxifylline modulates deformability, F-actin content, and superoxide anion production of polymorphonuclear leukocytes fromdiabetic cats. Experimental Eye Research 1992;55(6):831-8.
34. Sterne 2001 Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care; Meta-analysis in Context. London: BMJ Publishing Group, 2001:189-208.
35. WHO 1980 WHO Expert Committee on Diabetes Mellitus. Second report. Technical Report Series 646. Geneva. WHO, 1980.
36. WHO 1985 WHO Expert Committee on Diabetes Mellitus. World Health Organization, 1985. Technical Report Series 727.
37. WHO 1998 Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-53.